VX-950: More Good News For Hep C Treatment
In keeping with my promise to follow the development of Vertex’s new hepatitis C drug, VX-950, here’s the latest on the product from Dow Jones.
“Vertex Pharmaceuticals Inc. (VRTX) on Saturday said interim study data showed its investigational hepatitis C drug may shorten the duration of treatment time for patients. Of 175 hepatitis C patients given telaprevir, or VX-950, in combination with pegylated interferon and ribavirin, 70% achieved a rapid viral response rate at 12 weeks of dosing, compared with 39% of patients who received a placebo in combination with the two medicines, Vertex said in a statement.”
